Ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin share a conserved binding site on the ciliary neurotrophic factor receptor α chain*

Received for publication, April 28, 2008, and in revised form, August 25, 2008 Published, JBC Papers in Press, August 26, 2008, DOI 10.1074/jbc.M803239200

François Rousseau1, Sylvie Chevalier, Catherine Guillet, Elisa Ravon, Caroline Diveu, Josy Froger, Fabien Barbier, Linda Grimaud, and Hugues Gascan2

From the Unité Mixte INSERM 564, Bâtiment Montaleau, 4 Rue Larrey, 49033 Angers Cedex 01, France

Ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin are members of the four-helix bundle cytokine family. These proteins signal through a common tripartite receptor composed of leukemia inhibitory factor receptor, gp130, and ciliary neurotrophic factor receptor α. Binding to ciliary neurotrophic factor receptor α occurs through an interaction site located at the C terminus of the cytokine AB loop and αD helix, known as site 1. In the present study, we have generated a model of neuropoietin and identified a conserved binding site for the three cytokines interacting with ciliary neurotrophic factor receptor α. To identify the counterpart of this site on ciliary neurotrophic factor receptor α, its cytokine binding domain was modeled, and the physicochemical properties of its surface were analyzed. This analysis revealed an area displaying properties complementary to the site 1 of ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin. Based on our computational predictions, residues were selected for their potential involvement in the ciliary neurotrophic factor receptor α binding epitope, and site-directed mutagenesis was carried out. Biochemical, cell proliferation, and cell signaling analyses showed that Phe172 and Glu286 of ciliary neurotrophic factor receptor α are key interaction residues. Our results demonstrated that ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin share a conserved binding site on ciliary neurotrophic factor receptor α.

1 Supported by the Angers Agglomeration.
2 To whom correspondence should be addressed. Tel.: 33-2-41-35-47-31; Fax: 33-2-41-73-16-30; E-mail: hugues.gascan@univ-angers.fr.
3 The abbreviations used are: CNTF, ciliary neurotrophic factor; CLC, cardiotrophin-like cytokine; NP, neuropoietin; LIF, leukemia-inhibitory factor; IL, interleukin; STAT, signal transducer and activator of transcription; CBD, cytokine binding domain; mAb, monoclonal antibody; WT, wild type.

* This work was supported by Association Française contre les Myopathies (CIMATH) program of the region Pays de la Loire. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
Characterization of the CNTF-CNTFRα Binding Site

The IL-6 family of cytokines belongs to the “long chain” four-α helix bundle class, with an up-up down-down topology (7). The different secondary structures are named A–D from the N terminus to C terminus (Fig. 1). Crystallographic structures and site-directed mutagenesis studies have shown that these cytokines interact with their receptor through three different binding sites, numbered 1–3 by analogy with growth hormone (Fig. 1) (34, 35). Cytokines requiring an α chain, like CNTF, CLC, NP, IL-6, and IL-11, bind first to the receptor through a site 1 composed of residues from the C-terminal parts of the AB loop and the αD helix (Fig. 1).

Site 2 is located on solvent-exposed faces of the αA and αC helices and is important for binding to gp130. Site 3 is specific to the IL-6 family and corresponds to an additional signaling receptor binding site for LIFR in the case of CNTF, CLC, and NP.

The LIFR binding site is characterized by an FXKX motif located at the N terminus of the αD helix (36). The CNTF and CLC binding site 1 have been previously identified by site-directed mutagenesis (37, 38). These studies have shown that a conserved tryptophan residue and an RXXXD motif, which are located in the C-terminal parts of the AB loop and the αD helix, respectively, are required for CNTF and CLC interaction with CNTFRα. However, the counterpart of this contact site on CNTFRα is still unknown.

The aim of the present study was to determine the location of the binding site of CNTF, CLC, and NP on CNTFRα. For this purpose, NP was modeled, and its predicted binding site 1 was compared with the binding sites of CNTF and CLC. This analysis led us to identify a conserved binding site 1 among all of the CNTFRα ligands. Subsequently, the CNTFRα CBD was modeled, and its binding surface was analyzed to identify an area displaying physicochemical properties complementary to those of the CNTF, CLC, and NP binding site 1.

EXPERIMENTAL PROCEDURES

Sequence Alignments—CNTF, NP, CLC, LIF, cardiotrophin-1, oncostatin M, CNTFRα, IL-6α, and IL-12p40 sequences were retrieved from the Uniprot and GenBankTM data bases. Multiple sequence alignments were obtained using the T-Coffee (available on the World Wide Web) and GeneDoc (available on the World Wide Web) programs. CNTFRα and NP secondary structures were predicted using Network Prediction Server analysis at the Pôle Bioinformatique Lyonnais (Lyon, France) (39). Multiple sequence alignments were also represented with WebLogo (available on the World Wide Web) (40).

Molecular Modeling—NP was modeled by satisfaction of spatial constraints using the Modeler program based on multiple sequence alignments and secondary structure predictions (41). The structural coordinates of human CNTF (42) and LIF (43) were selected as molecular templates for the four-helical core of NP; the coordinates of an additional α helix predicted in the AB loop of these cytokines were computed with the Biopolymer module of InsightII (Accelrys, San Diego, CA) and integrated during the modeling process.

CNTFRα was modeled as previously reported (21). Additional refinements of the CNTFRα model were carried out by optimizing side chain conformation using SCWRL3 (44). Electrostatic potentials were computed using Adaptive Poisson-Boltzmann Solver with the AMBER force field (45, 46), and Eisenberg’s hydrophobicity scale was used to display the protein surface hydrophobicity (47).

Protein Docking—CNTF, NP, and CNTFRα were manually superimposed onto their respective partner in the IL-6IL-6α complex (Protein Data Bank accession number 1P9M) to build preliminary models. These models were further refined with the molecular docking program HEX 5.0 (48) to optimize structural complementarities. The best scoring solutions for each complex were energy-minimized with CHARMM (49) using the 100 steepest descent steps, followed by ABNR steps until a convergence gradient of 0.001 was reached.

Cells and Reagents—The COS-7, T98G glioblastoma, and SK-N-GP neuroblastoma cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum. The culture medium of Ba/F3 cells, modified to express the functional tripartite receptor for CNTF (BAF GLC), was supplemented with 5 ng/ml human CNTF (2). Anti-CNTFRα (AN-B2, AN-C2, and AN-E4) monoclonal antibodies and the polyclonal anti-CNTF
antibody were generated in the laboratory. The anti-protein C (HPC4) antibody was purchased from Roche Applied Science. The anti-STAT3 polyclonal antibody and the mAb-specific for phospho-705-STAT3 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and New England Biolabs (Beverly, MA), respectively. CNTF, LIF, and IL-2 were bought from R&D Systems (Oxon, UK). CLC and mouse NP were produced as previously described (1, 2).

**Site-directed Mutagenesis and Cell Transfection**—The cDNAs encoding NP and the membrane or soluble forms of CNTFRα were subcloned in the pcDNA3.1 vector and subjected to site-directed mutagenesis using the QuikChange™ site-directed mutagenesis kit (Stratagene, La Jolla, CA), following the manufacturer’s instructions. Mutations were verified by automatic DNA sequencing. cDNAs encoding mutant and wild-type CNTFRα were transfected by electroporation in T98G glioblastoma cells using the Amaxa Nucleofactor™ technology (Amaxa, Köln, Germany), following the manufacturer’s instructions. cDNAs encoding mutant and wild-type (WT) NP were transfected in COS-7 cells, as previously described (1). After a 48-h culture period, cells or supernatants were harvested and assayed. Mutant and WT NP were purified from the supernatant, as previously described (1).

**Tyrosine Phosphorylation Analysis and Western Blotting**—Parental or transfected T98G cells and SK-N-GP neuroblastoma cells were activated for 10 min with the indicated cytokines before being lysed in 10 mM Tris-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, protease inhibitors (1 μg/ml pepstatin, 2 μg/ml leupeptin, 5 μg/ml aprogin, 1 mM phenylmethylsulfonyl fluoride), and 1% Nonidet P-40. The lysates were subjected to SDS-PAGE and immunoblot analysis with a mAb specific for the tyrosine-phosphorylated form of STAT3. Membranes were stripped in 0.1 M glycine, pH 2.5, for 15 h and neutralized in 1 M Tris-HCl, pH 7.6, before reblotting with an antibody recognizing all STAT3 isoforms.

**Immunoprecipitation**—COS-7 cell supernatants containing the wild type or mutated forms of soluble CNTFRα were harvested 48 h after transfection. For co-immunoprecipitation experiments, the receptors were incubated at a concentration of 1 μM with 1 μM CNTF. Then proteins were incubated overnight with the AN-C2 anti-CNTFRα mAb at a concentration of 10 μg/ml. Complexes were isolated using beads coagulated to protein A, followed by SDS-PAGE. Western blot analysis was performed with an anti-protein C biotinylated mAb or an anti-CNTF biotinylated polyclonal antibody, and revealed by polystreptavidin peroxidase. The reaction was visualized using an image Master camera from Amersham Biosciences. Membranes were stripped as described above, before reblotting with the biotinylated anti-CNTFRα AN-E4 mAb.

**Flow Cytometry Analysis**—Parental and transfected T98G glioblastoma cells were incubated for 30 min at 4°C with anti-CNTFRα monoclonal antibodies (AN-B2 and AN-C2) (10 μg/ml) or an isotype control antibody before using a phycoerythrin-labeled polystreptavidin for an additional 30-min incubation step. Fluorescence was subsequently analyzed on a FACScalibur flow cytometer (BD Biosciences).

**Biological Assays**—BAF GLC cells were seeded in 96-well plates at a concentration of 5 × 10³ cells/well in RPMI 1640 medium containing 5% fetal calf serum. Serial dilutions of the cytokines tested were performed in triplicate. After a 72-h incubation period, 0.5 μCi of [³H]TdR was added to each well for the last 4 h of the culture, and the incorporated radioactivity was determined by scintillation counting, as previously described (51).

**RESULTS**

**Analysis of the CNTF, CLC, and NP Binding Site 1 and NP Modeling**—First, we performed a multiple sequence alignment of orthologs and paralogs of the IL-6 family members recruiting LIFR in their receptor complex (Fig. 2A). A conserved tryptophan residue (Trp⁶⁴ in CNTF and CLC, respectively), located in the AB loop of these cytokines was previously reported to contribute to their binding site 1 (37, 38). The alignment shows that Trp⁸⁵ in NP was highly conserved with CNTF Trp⁶⁴ and CLC Trp⁹⁴ and suggests that this residue is also involved in the NP site 1.

Additional residues in the αD helix of these cytokines also contribute to CNTF and CLC binding site 1 (37, 38). An RXXXD motif (Arg¹⁷² and Asp¹⁷⁵ in CNTF and Arg¹⁹⁷ and Asp²⁰¹ in CLC) is conserved in the C-terminal part of this α helix. Interestingly, this RXXXD motif was also present in the C-terminal part of the NP αD helix (Arg¹⁹⁰ and Asp¹⁹⁴). These observations suggested that, like CNTF and CLC, NP possesses a conserved binding site 1 for CNTFRα (Fig. 2A).

We built a NP molecular model using CNTF and LIF structures as templates. Next, we compared the NP model obtained with the CNTF structure or the CLC model previously reported (38, 42) and analyzed their binding site 1 (Fig. 2B). Strikingly, the NP binding surface involved a tryptophan residue located in the AB loop surrounded by positively charged residues, as already observed for CNTF and CLC. This clearly showed that the physicochemical properties of CNTF, CLC, and NP binding site 1 were conserved.

**Site-directed Mutagenesis of NP**—To confirm the modeling study, we generated the W85A NP mutant. As a control, an irrelevant F82A mutation, located in the vicinity of the area studied, was introduced into the NP sequence. WT and mutant forms of NP were expressed in the COS-7 cell line and purified on a Ni²⁺-nitrilotriacetic acid column, as previously described (1). The functionality of WT NP and mutant NP was tested in a proliferation assay using the BAF GLC cell line expressing the tripartite CNTF receptor complex. The results showed a lack of proliferation when cells were grown in the presence of the W85A NP mutant compared with the proliferation observed in the presence of the WT or F82A forms of NP (Fig. 3A).

In addition, the NP mutants were studied for their ability to induce the recruitment of the STAT3 signaling pathway in SK-N-GP, a neuroblastoma cell line expressing the three CNTF receptor chains (Fig. 3B). A robust STAT3 tyrosine phosphorylation was observed in response to WT or F82A CNTF, NP, or IL-2 as a control cytokine was revealed using phycoerythrin-labeled polystreptavidin for an additional 30-min incubation step. Fluorescence was subsequently analyzed on a FACScalibur flow cytometer (BD Biosciences).
mutant forms of NP as well as to CNTF. In contrast, W85A NP mutant failed to activate STAT3. To conclude, Trp 85 is a crucial residue for NP biological activities and is likely to contribute to the definition of a conserved site 1 among CNTF, CLC, and NP.

Molecular Modeling of CNTFRα—To identify counterpart(s) of the binding site 1 of CNTF, CLC, and NP on CNTFRα, we analyzed the CNTFRα model that we previously reported (21). For this purpose, we refined this model by optimizing the side chain conformation using SCRWL3. Cytokine-receptor complexes, solved by x-ray crystallography (34, 52), have revealed that several receptor loops contain residues involved in their binding interfaces. Indeed, loops connecting β strands E and F, B' and C', and F' and G' are parts of

FIGURE 2. Multiple sequence alignment of cytokines belonging to the IL-6 family and ribbon representation of the CNTF structure and CLC and NP models. A, dark blue-shaded letters indicate conserved or type-conserved amino acids according to the BLOSUM45 matrix. 80% conserved residues are shaded in cyan. The NP sequence is murine, and the other sequences are human. The figure shows the assignment of the four α helices of the cytokines represented as predicted by the secondary structure prediction server Network. Yellow boxes highlight residues implicated in the CNTF, CLC, and NP binding site 1. B, ribbon representation of the NP model displaying charged and aromatic residues in its binding site. Green residues, aromatic amino acids; blue residues, polar and positively charged.
the receptor binding sites (34, 52, 53). This observation prompted us to carefully analyze these elements in CNTFRα.

We performed a multiple sequence alignment of CNTFRα with other short α chain receptor orthologs and paralogs, including IL-6Rα and IL-12p40 (Fig. 4A). This alignment showed that β strands were globally conserved between the different receptors as well as apolar residues involved in the hydrophobic core of the proteins. However, connecting loops, including EF, B′C′, and F′G′ loops, were not conserved between the different receptors.

Analysis of the CNTFRα model indicated that the hinge region connecting the D2 and D3 domains harbored an aromatic cluster composed of five residues (depicted in green in Fig. 4B and C). These amino acids stabilized the CBD as commonly observed in this family of proteins (34, 52). However, we observed a structural divergence between the different α receptor chains when we analyzed the EF, B′C′, and F′G′ loops, which prevented identification of key CNTFRα interaction residues by homology with IL-6Rα and IL-12p40. Therefore, we studied the physicochemical properties of the CNTFRα surface and focused on the putative area(s) complementary to CNTF, CLC, and NP binding site 1.

**Determination of the Putative CNTFRα Binding Site**—To identify binding site complementary area(s), we computed and then compared the electrostatic potential of the CNTF and CNTFRα surfaces (Fig. 5). Indeed, residues Argβ25 and Argβ26, located in the CNTF αA helix, mainly contributed to a positively charged area, as previously reported (37, 42). Fig. 5C shows the presence of an extended negatively charged surface centered on CNTFRα Gluβ236 and Gluβ286, which forms a mirror image of the positively charged area of CNTF.

The hydrophobic potential was mapped onto the CNTF and CNTFRα surfaces. In agreement with previous studies (37, 42), Trpβ26 forms part of a hydrophobic pocket on the CNTF binding site 1 (Fig. 5B). A complementary residue, displaying similar physicochemical properties, was identified in the CBD hinge region of CNTFRα. It appears that the protruding side chain of Pheβ27 forms a hydrophobic patch complementary to the CNTF Trpβ26 pocket (Fig. 5D).

Moreover, we analyzed residue conservation in the EF, B′C′, and F′G′ interacting loops in different CNTFRα orthologs. Pheβ27, Gluβ236, and Gluβ286, located in these loops, were evolutionary conserved or type conserved residues (Fig. 5E). These results further sustained the idea that the three residues identified were potential CNTFRα binding hot spots.

We also performed the same analyses for CLC and NP. Strikingly, CLC Trpβ26, in agreement with our previous study (21), and NP Trpβ21 contributed to a hydrophobic pocket complementary to CNTFRα Pheβ27 (data not shown).

**Molecular Docking of CNTFRα with Its Ligands**—To further characterize the interaction of CNTFRα with its three ligands, molecular docking experiments were carried out. The IL-6-IL-6Rα complex was used as a template to build preliminary CNTF-CNTFRα and NP-CNTFRα models (the CLC-CNTFRα docking model was previously published (21)). The precise cytokine-receptor orientations were computed using HEX to
Characterization of the CNTF-CNTFRα Binding Site

FIGURE 5. Connolly surfaces of CNTF (A and B) and of the CNTFRα CBD (C and D) and residue conservation of CNTFRα-interacting loops (E). The electrostatic potentials (A and C) and the hydrophobic index of the exposed residues (B and D) were mapped onto the surfaces of CNTF and CNTFRα as described under “Experimental Procedures.” The orientations of CNTF and CNTFRα have been manually adjusted to provide an “open book” surface representation of the interfaces. E, conservation of residues present in CNTFRα-interacting loops are represented as logos. Each logo consists of stacks of symbols, one stack for each position in the sequence. The overall height of the stack indicates the sequence conservation at that position, whereas the height of symbols within the stack indicates the relative frequency of each amino acid at that position. Green residues, aromatic amino acids; blue residues, polar and positively charged; red residues, polar and negatively charged; black residues, hydrophobic; orange residues, polar and neutral.

optimize protein shape complementarities. Complexes with the best scoring solutions were then energy minimized to allow side chain reorientation at the cytokine-receptor interface. The CNTF-CNTFRα complex model is presented in Fig. 6 (the NP-CNTFRα complex appears as supplemental Fig. 1).

This model shows that the CNTF Trp64 and CNTFRα Phe172 are involved in an aromatic-aromatic interaction. In the vicinity of this hydrophobic area, a cluster of polar residues is formed by CNTF Arg25 and Arg28 located in the αA helix and CNTFRα Glu236 and Glu286 located in the D3 domain. These residues are predicted to form salt bridges between the two proteins. Additional charged residues (CNTF Arg177 and CNTFRα Asp234) might also contribute to the interaction by long range electrostatic effects. Similarly, CNTFRα Glu236 and Glu286 were also predicted to be involved in salt bridge or hydrogen bond with polar NP residues.

Site-directed Mutagenesis and Expression of the Mutated Forms of CNTFRα—Based on the above observations, we selected Phe172, Glu236, and Glu286 of CNTFRα as important residues for interaction with its different cognate ligands. Mutants were designed to alter the receptor binding capacities, and the following mutations were introduced: F172A, E236A, and E286A. In addition, Phe199 located in the vicinity of the potentially critical residue Phe172 was also mutated to alanine and used as irrelevant control for our model.

Corresponding cDNAs were transfected in the T98G human glioblastoma, a cell line expressing gp130 and LIFR, but not CNTFRα (1). A strong expression of both WT and mutated forms of CNTFRα was detected by FACS analysis (Fig. 7). A similar expression level was observed using either AN-B2 or AN-C2 antibody, two mAbs directed against different CNTFRα conformational epitopes (20). This finding indicates that the mutations introduced did not significantly alter CNTFRα folding and structure (Fig. 7).

Binding Properties of CNTFRα Mutants—The binding properties of CNTFRα mutants expressed in the T98G glioblastoma cell line were examined. For this purpose, CNTF and CLC were biotinylated and incubated with the transfected cells. Binding to the cell surface was monitored by fluorescence-activated cell sorting analysis (Fig. 8).

Readily detectable signals were measured when either CLC or CNTF was incubated with cells expressing WT CNTFRα or the F199A mutant. As expected, no binding could be detected when either CNTF or CLC were incubated with the T98G parental cell line. Importantly, a significant decrease or complete abrogation of CNTF and CLC binding was observed when the cytokines were added to the cells expressing either E286A or F172A forms of CNTFRα. In contrast, no significant change in cytokine interaction was seen for the E236A mutant (Fig. 8). Similar biotinylation experiments were carried out with NP, but major protein instability was observed during the labeling process. Therefore, we could not perform the binding analyses (data not shown). Together, these results indicate that CNTFRα Phe172 and Glu286 play an important role in CLC and
CNTF binding, in agreement with our molecular modeling study.

Mutant CNTFRα Association with CNTF and CLC—Previous studies have shown that a soluble form of CNTFRα can bind CNTF (20, 26). To monitor the interaction of soluble CNTFRα with CNTF, co-immunoprecipitation experiments were performed (Fig. 9A). Results showed that the soluble CNTFRα F172A and E286A mutants failed to interact with CNTF compared with the WT or F199A forms used as a control.

We previously reported that CLC was secreted as a composite cytokine when associated with a soluble receptor moiety that could be either cytokine-like factor 1 or soluble CNTFRα (2, 20). We studied the interaction between CLC and soluble CNTFRαs by co-expressing a tagged form of the cytokine together with the soluble receptor mutants in the COS-7 cell line. Co-immunoprecipitation experiments showed the secretion of a stable composite when CLC was co-expressed either with WT or F199A mutant (Fig. 9B). Interestingly, no stable heterocomplex formation of CLC with the F172A or E286A soluble receptors could be detected. However, a slight secretion of CLC was observed when co-expressed with the E286A CNTFRα mutant. This result underlines a transient interaction between the two proteins in agreement with the results presented in Fig. 8. Analysis of cell lysates confirmed the correct expression of both partner proteins. NP interaction with soluble CNTFRα mutants could not be assessed, since we previously reported that NP only recognized the membrane form of CNTFRα (1). These results indicate that CNTF and CLC interact predominantly with CNTFRα through the same residues, Phe172 and Glu286.

Functional Properties of CNTFRα Mutants—We examined the functional properties of CNTFRα mutants in response to CNTF, CLC, and NP. We analyzed the tyrosine phosphorylation level of STAT3, a major signaling pathway recruited by the tripartite CNTF receptor complex. Experiments were carried out using the T98G glioblastoma cell line transfected with CNTFRα mutants. LIF, which mediates its responses through
the gp130-LIFR heterocomplex, was used as a positive control (Fig. 10).

Western blot assays showed that CNTFRα is necessary to induce STAT3 phosphorylation in response to CNTF, CLC, or NP. A nearly total extinction of the signal was observed when cells were transfected with F172A or E286A receptor mutants and activated with CNTFRα ligands. In the cells expressing the E236A mutant or the F199A mutant, the STAT3 pathway remained sensitive to stimulation with the three ligands. These combined results corroborate the modeling and binding results of the study.

**DISCUSSION**

CNTFRα is able to specifically recognize three different ligands sharing 16–25% sequence identity. Previous studies have identified binding site 1 of CNTF and CLC (37, 38), but its counterpart on CNTFRα has not yet been described to date regarding the binding site 1 counterpart on CNTFRα. We therefore undertook the identification of the molecular determinants implicated in the interaction of CNTFRα with its ligands, in order to understand its cross-reactivity.

The resolution of cytokine-receptor complexes by crystallography has determined the molecular assembly of this family of proteins (34, 52–54). It first revealed that this protein-protein assembly requires complementary shapes and physicochemical properties. Moreover, site-directed mutagenesis experiments have demonstrated that only a few residues, defined as interac-

![FIGURE 8. Binding of CNTF and CLC on T98G glioblastoma cells transfected with wild type or mutant CNTFRα receptors and analyzed by flow cytometry. White histograms correspond to the control signals. Gray and dark histograms represent CNTF and CLC binding, respectively.](image)

![FIGURE 9. Co-immunoprecipitation of CNTF and CLC and secretion of CLC with mutant forms of CNTFRα. A, 1 nM soluble wild type or mutant CNTFRα and CNTF were immunoprecipitated (IP) using the anti-CNTFRα (AN-C2) mAb, and CNTF was visualized by Western blot (WB). B, mutant or WT soluble CNTFRα was co-synthesized with a protein C-tagged form of CLC in COS-7 cells to allow for the formation of the composite cytokine. Culture supernatants were harvested before immunoprecipitation of the CLC/CNTFRα complex using the anti-CNTFRα (AN-C2) mAb or CLC using the anti-protein C mAb. CLC was then visualized by Western blot using the anti-protein C antibody. The presence of CLC and CNTFRα was also controlled in the lysate of the transfected cells. Membranes were stripped before reblotting with the biotinylated anti-CNTFR AN-E4 mAb as a control.](image)

![FIGURE 10. Induction of STAT3 tyrosine phosphorylation in T98G cells transfected with wild type or mutant CNTFRα. Parental and transfected T98G glioblastoma cells were incubated for 10 min with 1 ng/ml LIF, CNTF, CLC, or NP, as indicated. Cells were then lysed and subjected to Western blotting using an anti-phospho-STAT3 (STAT-3P) or an anti-STAT-3 (STAT-3) antibody.](image)
tion hot spots, contribute to the binding free energy (55). Statistical analyses of numerous receptor binding sites have revealed that hot spots are often conserved and are significantly enriched in aromatic amino acids (56).

These notions were used to look for the complementary site 1 of CNTFRα. In the present study, we have shown that CNTF, CLC, and NP share the same binding site 1. The CNTFRα putative structural binding epitope was determined by searching a surface area with physicochemical properties complementary to the binding site 1 of CNTF, CLC, and NP. To reinforce the modeling prediction, the residues identified were substituted with alanine, and the mutants obtained were further tested in a panel of biological assays.

Both Panayotatos’s group and ours previously reported the involvement of the conserved residues CNTF Trp64 and CLC Trp94 for the interaction of these cytokines with CNTFRα (37, 38). Additional residues also contribute to CNTF and CLC binding site 1. An RXXXD motif (CNTF Arg172 and Asp175 and CLC Arg197 and Asp201) is conserved in their αD helix and is essential for the side chain orientation of the tryptophan residue hot spot (37, 42). Furthermore, we have identified inactivating mutations in the gene coding for CLC in a patient suffering from cold-induced sweating syndrome (21). One of these mutations, a substitution of Arg197, impairs the CLC/CNTFRα interaction. This observation confirms the importance of RXXXD motif for the integrity of binding site 1.

In the present study, we characterized the NP binding site 1, which is conserved across the three CNTFRα ligands. The NP Trp85 residue, equivalent to CNTF Trp64 and CLC Trp94, was found to be a hot spot at the interface of the NP-CNTFRα complex. Interestingly, an RXXXD motif was also conserved in the αD helix of NP (Arg190 and Asp194). The determination of a conserved site 1 for CNTF, CLC, and NP was the starting point for our investigation of the CNTFRα binding epitope.

The structural diversity of the receptor-interacting loops led us to compute surface physicochemical properties of CNTFRα in order to identify complementarities with CNTF, CLC, and NP binding surfaces. A mirror image of the three cytokines’ binding site 1 was found on CNTFRα. The residues, Phe172, Glu286, and Glu286, were identified as potential components of its binding epitope. Our study clearly established that the F172A and E286A CNTFRα mutations impaired or decreased CNTF, CLC, and NP interactions.

The F172A mutation in the EF loop of the CNTFRα domain completely abrogated the binding of CNTF, CLC, and NP with this receptor. Moreover, the CNTFRα F172A mutant failed to mediate biological responses induced by these three cytokines. These results confirmed the data obtained with CNTF W64A, CLC W94A, and NP W85A mutants (37, 38). Our docking study indicated that these tryptophan residues were involved in aromatic-aromatic interactions with CNTFRα Phe172. The highly disruptive effects of corresponding mutations further confirmed that Phe172 was a hot spot residue on the CNTFRα surface.

Similarly, the E286A mutation impaired biological activity mediated through CNTFRα in response to CNTF, CLC, and NP. A salt bridge between CNTF Arg25 and CNTFRα Glu286 was observed in the CNTF-CNTFRα complex model that we generated. These observations fit with results obtained with the CNTF Arg25 mutant, which also lost its CNTFRα recognition capacity (37).

Analysis of the related cytokine-receptor α chain complexes shows that aromatic-aromatic and salt bridge interactions are globally conserved at these protein interfaces (34, 52). In the IL-6-IL-6Rα structure, the IL-6Rα Phe248 residue is critical for the interaction with IL-6 Phe106 located in the cytokine AB loop, as supported by mutational experiments (34, 57). A similar situation was observed for IL-12p35-IL-12p40, where the IL-12p40 Tyr246 residue and its paring residue (Tyr193) present in the αD helix of p35 were found to be important in the interaction of the IL-12p35 and IL-12p40 subunits (52). Conserved salt bridges between IL-6 Arg287 and IL-6Rα Glu296 or IL-12p35 Arg239 and IL-12p40 Glu293 are also important for cytokine-receptor binding.

The present work, as well as previous studies (34, 52), suggests that despite structural divergence of receptor-interacting loops, the different cytokines and receptors of the IL-6/IL-12 family have kept similar intermolecular interactions in order to associate with each other. Importantly, conserved pairs of aromatic or charged residues on these protein interfaces seem to be a conserved feature of cytokines and receptors interacting through a binding site 1 in the IL-6/IL-12 family. This finding could help to identify crucial residues involved in the interactions of newly described composite cytokine subunits, such as IL-23, IL-27, or IL-35 (6, 58–60).

In conclusion, CNTF, CLC, and NP share an overlapping binding epitope located in the CNTFRα CBD and involving Phe172 and Glu286 residue hot spots. The CNTFRα Phe172 residue is the mirror image of the conserved tryptophan hot spot identified in CNTF, CLC, and NP. These pairs of residues are predicted to form an aromatic-aromatic interaction at the cytokine/receptor interface. The CNTFRα Glu286 residue is a hot spot residue at the CNTF/CNTFRα and NP/CNTFRα interfaces and plays a major role in CLC-CNTFRα complex stability.

Acknowledgments—We thank G. Elson for careful review of the manuscript and D. Perret for stimulating discussions in the early phase of the project.

REFERENCES

1. Derouet, D., Rousseau, F., Alfonsi, F., Froger, J., Hermann, J., Barbier, F., Perret, D., Diveu, C., Guillett, C., Preissler, L., Dumont, A., Barbado, M., Morel, A., deLapeyriere, O., Gascan, H., and Chevalier, S. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 4827–4832

2. Elson, G. C., Lelievre, E., Guillett, C., Chevalier, S., Plun-Favreau, H., Froger, J., Stuard, L., et al. (2005) J. Biol. Chem. 280, 10551–10559

3. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998) Biochem. J. 334, 297–314

4. Perret, D., Diveu, C., et al. (2005) J. Biol. Chem. 280, 10551–10559

5. Taga, T., and Kishimoto, T. (1997) Annu. Rev. Immunol. 15, 797–819

6. Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibi, H., Churakov, T., et al. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 12324–12329

7. Panayotatos, N. (1998) Blood 92, 3495–3504

8. Curtis, R., Adryan, K. M., Zhu, Y., Harkness, P. J., Lindsay, R. M., and Di Stefano, P. S. (1993) Nature 365, 253–255
